{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:33:59Z","timestamp":1768883639053,"version":"3.49.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R\/R cHL) following, or who were ineligible for, autologous stem cell transplantation (ASCT). Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported from patients who received \u22651 dose of study treatment and completed \u22651 PRO assessment. The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were administered at baseline, every 6 weeks until week 24, and every 12 weeks thereafter. Prespecified end points included least squares mean (LSM) changes from baseline to week 24 and time to true deterioration (TTD; \u226510-point decline from baseline). Comparisons were evaluated using 2-sided P values uncontrolled for multiplicity. High compliance at baseline (&amp;gt;90%) and through week 24 (&amp;gt;80%) was demonstrated across treatment groups (PRO analysis set: pembrolizumab, n = 146; BV, n = 150). The EORTC QLQ-C30 global health status (GHS)\/quality of life (QoL) score improved from baseline to week 24 on pembrolizumab and worsened on BV and demonstrated significant LSM differences at 24 weeks (GHS\/QoL: 8.60 [95% confidence interval, 3.89-13.31]; P = .0004). Significant improvements were observed in each QLQ-C30 domain except emotional and cognitive functioning. Compared with BV, pembrolizumab prolonged TTD for GHS\/QoL (hazard ratio, 0.40 [95% CI, 0.22-0.74]; P = .003) and each QLQ-C30 domain except cognitive functioning. In conclusion, pembrolizumab demonstrated overall improvements in PROs of HRQoL measures over BV in the KEYNOTE-204 study. These data and previously reported efficacy results support pembrolizumab as the preferred treatment option for patients with R\/R cHL who are ineligible for or experience relapse after ASCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004970","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T06:21:41Z","timestamp":1634538101000},"page":"590-599","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, Bologna, Italy;"},{"name":"Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 di Bologna, Bologna, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Tennessee, Knoxville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-3932","authenticated-orcid":false,"given":"Ewa","family":"Paszkiewicz-Kozik","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-8757","authenticated-orcid":false,"given":"Robin","family":"Gasiorowski","sequence":"additional","affiliation":[{"name":"Department of Hematology, Concord Hospital, University of Sydney, Sydney, NSW, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jewish General Hospital Montreal, Montreal, QC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose S. R.","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Casa de Sa\u00fade Santa Marcelina, S\u00e3o Paulo, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6999-4109","authenticated-orcid":false,"given":"Valeria","family":"Buccheri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hospital das Clinicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Fleury","family":"Perini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Israelita Albert Einstein, S\u00e3o Paulo, Brazil;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1492-5966","authenticated-orcid":false,"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Pretoria East Hospital, Pretoria, South Africa;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-1918","authenticated-orcid":false,"given":"Muhit","family":"\u00d6zcan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Raut","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd L.","family":"Saretsky","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Nahar","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"issue":"5","key":"2022011916244266200_B1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz","year":"2004","journal-title":"Br J Haematol."},{"issue":"5","key":"2022011916244266200_B2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3324\/haematol.2011.047670","article-title":"Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin\u2019s lymphoma resistant to platinum-containing first-line salvage chemotherapy","volume":"97","author":"Villa","year":"2012","journal-title":"Haematologica."},{"issue":"1","key":"2022011916244266200_B3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/bloodadvances.2019000984","article-title":"Five-year results of the BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma","volume":"4","author":"Santoro","year":"2020","journal-title":"Blood Adv."},{"issue":"32","key":"2022011916244266200_B4","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.15.5507","article-title":"Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin\u2019s lymphoma","volume":"26","author":"Goodman","year":"2008","journal-title":"J Clin Oncol."},{"key":"2022011916244266200_B5","volume-title":"Patient-reported outcome measures: use in medical product development to support labeling claims.","author":"Guidance for Industry","year":"2009"},{"issue":"1","key":"2022011916244266200_B6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12955-016-0515-6","article-title":"Health-related quality of life in Hodgkin lymphoma: a systematic review","volume":"14","author":"Linendoll","year":"2016","journal-title":"Health Qual Life Outcomes."},{"key":"2022011916244266200_B7","volume-title":"ADCETRIS (brentuximab vedotin) for injection, for intravenous use [package insert].","year":"2019"},{"key":"2022011916244266200_B8","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): Hodgkin lymphoma","author":"National Comprehensive Cancer Network"},{"issue":"25","key":"2022011916244266200_B9","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood."},{"issue":"5","key":"2022011916244266200_B10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/bjh.14316","article-title":"Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma","volume":"175","author":"Ramsey","year":"2016","journal-title":"Br J Haematol."},{"issue":"6","key":"2022011916244266200_B11","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"23","key":"2022011916244266200_B12","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1\u00a0and\u00a0PD-L2\u00a0genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol."},{"key":"2022011916244266200_B13","volume-title":"OPDIVO (nivolumab) injection, for intravenous use [package insert].","year":"2019"},{"key":"2022011916244266200_B14","volume-title":"KEYTRUDA (pembrolizumab) for injection, for intravenous use [package insert].","year":"2020"},{"issue":"14","key":"2022011916244266200_B15","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol."},{"issue":"14","key":"2022011916244266200_B16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2022011916244266200_B17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"issue":"11","key":"2022011916244266200_B18","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/10428194.2019.1602262","article-title":"Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma","volume":"60","author":"von Tresckow","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022011916244266200_B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022011916244266200_B20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol."},{"issue":"9828","key":"2022011916244266200_B21","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet."},{"key":"2022011916244266200_B22","doi-asserted-by":"crossref","first-page":"2040620720902911","DOI":"10.1177\/2040620720902911","article-title":"Optimizing outcomes in relapsed\/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies","volume":"11","author":"Vassilakopoulos","year":"2020","journal-title":"Ther Adv Hematol."},{"issue":"5","key":"2022011916244266200_B23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol."},{"key":"2022011916244266200_B24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","article-title":"Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma","volume":"67","author":"Schadendorf","year":"2016","journal-title":"Eur J Cancer."},{"issue":"16","key":"2022011916244266200_B25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022011916244266200_B26","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"2022011916244266200_B27","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1080\/10428194.2019.1573368","article-title":"Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-na\u00efve patients","volume":"60","author":"Lepik","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2022011916244266200_B28","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s11136-020-02520-7","article-title":"Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings","volume":"29","author":"Joseph","year":"2020","journal-title":"Qual Life Res."},{"issue":"4","key":"2022011916244266200_B29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"2022011916244266200_B30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jamaoncol.2016.3328","article-title":"Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials","volume":"3","author":"Atkinson","year":"2017","journal-title":"JAMA Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/590\/1860719\/advancesadv2021004970.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/2\/590\/1860719\/advancesadv2021004970.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T16:30:04Z","timestamp":1642609804000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/2\/590\/477276\/Quality-of-life-analysis-of-pembrolizumab-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004970","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]}}}